Search

Search Constraints

You searched for: Author/Creator Verdú, Ana

Search Results

1. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). (December 2020)